Biostem Technologies Inc. (BSEM)
OTC PINK OTC PINK Primary 
BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal
BioStem Technologies OTCMKTS: BSEM outlined its strategy to expand in surgical applications, shift its revenue mix away from physician-office wound care and bring manufacturing of acquired products into its Florida facility.
BioStem Technologies Q2 Earnings Call Highlights
BioStem Technologies OTCMKTS: BSEM reported second-quarter revenue of $7.9 million as the company continued its transition to a predominantly hospital-focused commercial model. Revenue increased from $6.1 million in the first quarter, supported by higher hospital sales, expanded commercial coverage and a full quarter of contribution from its acquired business.
BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates
BioStem Technologies, Inc. (BSEM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to earnings of $0.11 per share a year ago.
BioStem Technologies Q1 Earnings Call Highlights
BioStem Technologies OTCMKTS: BSEM said its first quarter of 2026 marked a major shift in its business model following a late-January acquisition that moved the company's focus from physician offices toward the hospital market.
BioStem Technologies, Inc. (BSEM) Q1 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Q1 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Reports Q1 Loss, Tops Revenue Estimates
BioStem Technologies, Inc. (BSEM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.17 per share a year ago.
BioStem Technologies Reports First Quarter 2026 Financial Results
POMPANO BEACH, Fla., May 14, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the first quarter ended March 31, 2026.
BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026
POMPANO BEACH, Fla., April 08, 2026 (GLOBE NEWSWIRE) — BioStem Technologies® (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing and commercialization of perinatal tissue allograft products, today announced its participation in the Symposium on Advanced Wound Care (SAWC) Spring meeting in Charlotte, NC, from April 8-12.
BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference
POMPANO BEACH, Fla., March 31, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference.
BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025
The Company continues its progression towards a Nasdaq uplisting POMPANO BEACH, FL, March 30, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies, Inc. (BSEM) Q4 2025 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Q4 2025 Earnings Call Transcript
